Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMF vs Rituximab for Refractory AIHA in SLE
NCT05057481Phase 3Unknown
- Sponsor
- Assiut University
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate mofetil in autoimmune hemolytic anemia (AIHA) (2 arms), sponsored by Assiut University. Primary endpoints: Complete Response proportion at 12 weeks, Partial Response proportion at 12 weeks and 1 more. Status: unknown.
02
Drugs
mycophenolate mofetil
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT05057481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057481.